

### Quality Variation and Clinical Impact in Head and Neck IMRT

6<sup>th</sup> IMRT Symposium, New York Sep. 20, 2010

#### K.S. Clifford Chao, MD


Chairman, Combined Radiation Oncology, New York Presbyterian Hospital Chairman, Radiation Oncology, Columbia University College of P & S Chief, Radiation Oncology, Weill Cornell Medical College

# Tumor Control by IMRT vs non-IMRT in Patients with Oropharyngeal Carcinoma


<u>]</u>	Patient No.	Median F/U	2yr LRC	2yr DFS
Def. Non-IMRT	153	3.5 yr (1.6-17.7)	68.3%	58.4% _
Def. IMRT	31	3 yr (12-58)	87.5%	73.5% -
Post-op Non-IMR	RT 142	3.9 yr (1.3-19.8)	75.7% —	73.5% -
Post-op IMRT	43	2.8 yr (9-60)	95.0%	94.3% -


## T2N1M0 SCC of Base of the Tongue






## T2N1M0 SCC of Base of the Tongue






Chao et al. Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50.

## Consensus on Nodal Level Delineation UCL, Erasmus, RTOG, EORTC, DAHANCA, GORTEC



## PET/MRI/CT— GTV Boundary




Average Mismatch of Laryngeal GTVs between Imaging Modalities and the Surgical Specimen

Pair	Mismatched Volume (%)
СТ	
To MR imaging	26 (6.2/23.8)
To FDG PET	48 (7.8/16.3)
To specimen	81 (10.2/12.6)
MR imaging	
To CT	45 (9.3/20.8)
To FDG PET	67 (11.0/16.3)
To specimen	107 (13.4/12.6)
FDG PET	
To CT	17 (3.5/20.8)
To MR imaging	15 (3.6/23.8)
To specimen	46 (5.8/12.6)
Specimen	
To CT	10 (2.0/20.8)
To MR imaging	9 (2.2/23.8)
To FDG PET	13 (2.1/16.3)


Daisne et. al. Radiology 233(1):93-100, 2004


## **Nodal CTV Delineation – Margin?**




# Microscopic Tumor Extension outside Nodal Capsule

- 97 ECE+ LNs from 49 patients
- Tumor extension through the LN capsule by:
  - Ø Actual presence of tumor cells
  - ø Desmoplasia (associated stromal reaction)
  - Ø Giant cell reaction to keratin
- Greatest linear distance perpendicular from external capsule border to furthest extent of tumor
  - Ø Nearest tenth of millimeter with micrometer
  - ø Extrapolation when appropriate
- Largest axial diameter of LN









## Results


- 96% ECE within 5 mm of capsule
- None beyond 10 mm
- Inverse correlation between ECE incidence and distance from capsule



## Results



- No correlation between LN and extent of ECE
- Mean ECE
  - ø LN < 1 cm: 2.1 mm
  - ø LN > 1 cm: 2.2 mm



Apisarnthanarax et al. Int J Radiat Oncol Biol Phys. 64:678, 2006

## **HN IMRT Challenges Ahead**

 Significant growth of IMRT accompanied by increase in time-consuming contouring

Significant variation in target determination and delineation

### **Cancer**, 1977

### Variation among RadOnc Physicians Exists

## THE STUDY OF THE PATTERNS OF CANCER CARE IN RADIATION THERAPY

SIMON KRAMER, MD

E valuation of the quality of care has become a critical issue in medical practice, and it is particularly important in the management of cancer patients where we are almost always dealing with life-threatening illness. The

practice with a wide geographic distribution (Table 1). Dr. David F. Herring has been an important contributor since inception of the study.


We have felt it extremely important to estab-

"I must hasten to add that for disease sites examined, many more variances appear, ....."

## Treatment portals for elective radiotherapy of the neck: an inventory in The Netherlands

Peter Nowak\*, Erik van Dieren, John van Sörnsen de Koste, Henry van der Est, Ben Heijmen, Peter Levendag

Department of Radiation Oncology, Dr. Daniel den Hoed Cancer Center/University Hospital Rotterdam-Dijkzigt, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands



#### Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):972-5

#### CLINICAL INVESTIGATION

**Head and Neck** 


AN EVALUATION OF THE VARIABILITY OF TUMOR-SHAPE DEFINITION DERIVED BY EXPERIENCED OBSERVERS FROM CT IMAGES OF SUPRAGLOTTIC CARCINOMAS (ACRIN PROTOCOL 6658)

JAY S. COOPER, M.D.,\* SURESH K. MUKHERJI, M.D.,<sup>†‡</sup> ALICIA Y. TOLEDANO, Sc.D.,<sup>§</sup> CLIFFORD BELDON, M.D.,<sup>¶</sup> ILONA M. SCHMALFUSS, M.D., <sup>∥</sup> ROBERT AMDUR, M.D., <sup>#</sup> SCOTT SAILER, M.D.,\*\* LAURIE A. LOEVNER, M.D.,<sup>††</sup> PHIL KOUSOUBORIS, M.D., <sup>‡‡</sup> K. KIAN ANG, M.D., PH.D.,<sup>§§</sup> JEAN CORMACK, PH.D., § AND JOREAN SICKS, M.S.

## Four neuroradiologists Four radiation oncologists

Contoured GTV on 20 laryngeal cancer CT images

One to one comparison of concordance



Degree of GTV Agreement


Range from 0% to 81.8% Average 53.17 +/- 3.8%

# Variations in CTV Target Delineation for Head and Neck IMRT


### **An International Survey**

Theodore S. Hong, Wolfgang A. Tomé, Richard J. Chappell, Paul M. Harari

University of Wisconsin
Department of Human Oncology



H&N IMRT Practice Heterogeneity




Courtesy of Dr. Harari

### Local failure in RTOG-0022 protocol variations

 4 of 53 patients with evaluable plans had major protocol variations due to underdose of PTV66.

#### Local recurrence:

- 2/4 (50%) patients with major PTV66 variation (underdose)
- -3/49 (6%) patients without major PTV66 variations
- -P=0.04



Treatment plan of a patient with a major PTV66 underdose

# Phase III Registration Trial TROG 02.02 (HeadSTART)

Patients with Stage III or IV SCCHN (stratified by stage, site, hemoglobin)



Randomization




Cisplatin, RT




• Tirapazamine, cisplatin, RT

# Accrual - 861 patients from 89 sites in 16 countries (Sep 02 – Apr 05)



## RT Volume Variation Adversely Impacts Tumor Control

Patients who had received at least 60Gy of RT to PTV2



### Advanced Knowledge-based Intelligent Tool





doi:10.1016/j.ijrobp.2007.04.037


#### PHYSICS CONTRIBUTION

## REDUCE IN VARIATION AND IMPROVE EFFICIENCY OF TARGET VOLUME DELINEATION BY A COMPUTER-ASSISTED SYSTEM USING A DEFORMABLE IMAGE REGISTRATION APPROACH

K. S. Clifford Chao, M.D.,\* Shreerang Bhide, FRCR,† Hansen Chen, M.S.,‡ Joshua Asper, PAC,\*
Steven Bush, M.D.,§ Gregg Franklin, M.D., Ph.D.,§ Vivek Kavadi, M.D.,
Vichaivood Liengswangwong, M.D.,¶ William Gordon, M.D.,\* Adam Raben, M.D.,‡
Jon Strasser, M.D.,‡ Christopher Koprowski, M.D.,‡ Steven Frank, M.D.,\*
Gregory Chronowski, M.D.,\* Anesa Ahamad, M.D.,\* Robert Malyapa, M.D., Ph.D.,\*\*
Lifei Zhang, Ph.D.,†† and Lei Dong, Ph.D.,††

\*Department of Radiation Oncology, the University of Texas M. D. Anderson Cancer Center, Houston, TX; †Department of Head & Neck Oncology, Royal Marsden Hospital, London, United Kingdom; †Department of Radiation Oncology, Christiana Care Health Services, Newark, DE; \*IKOE Education and Training Unit, Houston, TX; Department of Radiation Oncology, New Mexico Cancer

### **Knowledge-based Computer-assisted Target Delineation**



Winston-Salem, March 29, 2007


## **IMRT** Target Dose Specification

Target	H&N IMRT			
Volume	Butler	RTOG H-0022	Lee	Chao
Concurrent Chemotherapy	NO	NO	Yes	Yes
	All Site s	Early Oropharyns	NPC	All Site :
<b>CTV1</b> 70Gy/35fx	60/2.4Gy 25fx	66/2.2Gy 30fx	70/2.12Gy 33fx	70/2Gy 35fx
<b>CTV2</b> 60 Gy/30fx	-	60/2Gy	59.4/1.8Gy	63/1.8Gy
<b>CTV3</b> 50 Gy/25fx	50/2Gy	54/1.8Gy	54/1.64Gy	56/1.6Gy

### Target Delineation and Dose Spec in 2010

Definitive	CTV1	CTV2	CTV3
IMRT	70/2.0	63/1.8	56/1.6
35 fx			
IMRT	70/2.1	60/1.8	54/1.6
33 fx			
2D	70/2.0	60/2.0	50/2.0
35 fx			

Post-op	CTV1	CTV2	CTV3
IMRT	63/2.1	60/2.0	54/1.8
30 fx			
2D	66/2.0	60/2.0	50/2.0
30 fx			



**T2N1M0 SCC of Base of the Tongue** 

# Summary

- Do no harm with evidence-based guidance
- Image-pathological study to refine GTV-CTV
- Bridging knowledge gap